CardioDynamics Announces Results of Two Significant BioZ Accuracy Studies at the CHEST 1999 Meeting, Chicago.

SAN DIEGO--(BW HealthWire)--Nov. 4, 1999--

CardioDynamics International Corp. (Nasdaq:CDIC), manufacturer of BioZ(R) noninvasive digital cardiac output monitoring systems, announced the results of two significant BioZ accuracy studies which were presented at the American College of Chest Physicians (ACCP) CHEST 1999 Meeting held Oct. 31 - Nov. 4, 1999 in Chicago.

The studies further validated that CardioDynamics' proprietary noninvasive Thoracic Electrical Bioimpedance (TEB) technology accurately measures cardiac output as compared to measurements by Intermittent Bolus Thermodilution (IBTD) from a Pulmonary Artery Catheter (PAC), as well as the long standing "gold standard," Direct Fick.

One study, the BioZ/PAC Critically Ill Patient Comparison Study, involved over 50 mechanically ventilated patients in a combined surgical and medical care unit at John Peter Smith Hospital in Forth Worth, Texas. Over 100 simultaneous BioZ and PAC cardiac output measurements were compared and the results revealed an impressive correlation (r=0.89, Bias: -0.446 L/min).

Daniel W. Ziegler, M.D., FCCP, FACS, director of the ICU at John Peter Smith Hospital and Clinical Instructor of Surgery at University of Texas, Southwestern Medical Center, Dallas, and chief investigator of the study, stated, "We are very excited with the results of the study validating the BioZ's precision in measuring cardiac output compared to the PAC procedure in mechanically ventilated patients. The BioZ is an important tool to accurately monitor cardiac output and to assist in directing and assessing treatment in intensive care patients. In view of the potential life threatening complications and high costs associated with the PAC, the BioZ provides a noninvasive and benign alternative method of monitoring cardiac output. This study is encouraging and may lead to the BioZ becoming a standard of care."

The company also announced that the results of the Pulmonary Hypertension BioZ/Fick Correlation Comparison Study were presented at CHEST 1999 by Gordon L. Yung, M.D. of the University of California at San Diego. The study's results demonstrated that the BioZ's measurement of cardiac index in pulmonary hypertension patients was almost identical to the Thermodilution measurement when both were compared to the true "gold" standard, Direct Fick (BioZ: r=0.84, Bias -0.14, Precision 0.44; Thermodilution: r=0.87, Bias 0.09, Precision 0.42).

Although the PAC procedure is currently the method most commonly used for cardiac assessment, its annual U.S. costs are estimated at $2 billion and associated complications run as high as 25% and include arrhythmias, infection, pulmonary artery rupture, and death.

Michael K. Perry, chief executive officer of CardioDynamics, stated, "The results of these significant accuracy studies, together with the results of ten recent clinical studies, continue to validate the accuracy and importance of the BioZ to the 360,000 monitored critical care hospital beds, 7,800 emergency departments, and 63,000 internal medicine/cardiology offices in the U.S. The medical community's increasing awareness of the BioZ's clinical and financial value is moving us closer to establishing the BioZ as the Sixth Vital Sign(TM)."

Company Description

CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, the BioZ(R) System, Portable BioZ(R) and BioZ.com(TM), utilize its proprietary Thoracic Electrical Bioimpedance (TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters. There are over 300 BioZ(R) systems now in use in major medical centers including the Mayo Clinic (Rochester), UCSF Stanford Health Care, (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for the BioZ(R) products is estimated to be $4 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cardiodynamics.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(TM) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1998 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.